Scientists at St. John’s University, The University of Pennsylvania and Université de Montréal have identified poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the ...

There are three types of PARP inhibitors approved to treat ovarian cancer — olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula). The drugs are largely similar in how they work with slight ...

Results from the PAOLA-1 study showed that the PARP inhibitor drug significantly increased the time women lived without disease progression when added to the standard-of-care, Genentech’s ...

Patients taking PARP inhibitors should have regular lab tests of red blood cell, white blood cell, and platelet counts. If side effects occur, dotors can consider adjusting dosage or temporarily ...

Niven Mehra discussing utilization of PARP inhibitors alone or in combination. Dr. Mehra started his presentation by emphasizing the importance of biomarker testing, given that many genes in the HRR ...

Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...

[48–50] Final data remain to be published. Table 1. Poly-(ADP-ribose) polymerase inhibitors in clinical studies. PARP inhibitor Number of completed or ongoing studies Type of studies completed ...

1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas. *Corresponding Author: Yago Nieto, Department of Stem Cell ...